A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Zuclopenthixol
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Volociximab
The risk or severity of adverse effects can be increased when Volociximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Catumaxomab
The risk or severity of adverse effects can be increased when Catumaxomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lexatumumab
The risk or severity of adverse effects can be increased when Lexatumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lerdelimumab
The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bivatuzumab
The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sibrotuzumab
The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Siplizumab
The risk or severity of adverse effects can be increased when Siplizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lucatumumab
The risk or severity of adverse effects can be increased when Lucatumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Coltuximab ravtansine
The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Trastuzumab deruxtecan.
Zuclopenthixol
XmAb 2513
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Carotuximab
The risk or severity of adverse effects can be increased when Carotuximab is combined with Trastuzumab deruxtecan.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3